NeurAxis Gaining Total Addressable Market Without Market Appreciation

NeurAxis (NRXS) remains our flagship stock. The company reported last Friday that it had been cleared by the FDA to treat pain associated with functional dyspepsia and nausea in the adult patient population. Note the careful wording of the press release and the time lag between the actual approval and its publication. The FDA approval was issued a week …